Search

Arindam Halder, Ajay J Khopade Formulation Department, Sun Pharmaceutical Industries, Ltd, Tandalja, Vadodara, IndiaCorrespondence: Ajay J KhopadeSun Pharmaceutical Industries, Ltd., Tandalja, Vadodara 390020, Gujarat, IndiaTel +91 22 6645 5645 Ext 1900Email ajay.khopade@sunpharma.comPurpose: Prostaglandin derivatives are used widely to reduce intraocular pressure associated with open-angle glaucoma. The most widely used prostaglandin derivative, latanoprost, is available in an ophthalmic solution that is solubilized and preserved with 0.02% benzalkonium chloride (BAK), which has been shown to be cytotoxic to corneal cells. Latanoprost ophthalmic solution with BAK requires specific storage temperatures, which can impact the supply cycle. Here, we describe the production, physicochemical characteristics, and cytotoxicity profile of a micelle formulation that solubilizes latanoprost without the need for BAK.Methods: The optimum concentration of castor oil with the surfactant polyethylene glycol (15) hydroxystearate was determined, and the mixture stirred. Various surfactants were tested to determine the ideal mixture to form a micelle formulation. Viscosity, zeta potential, surface tension, droplet size, and osmolality of the batches were tested. The cytotoxicity of the micelle formulation was determined in a corneal cell viability assay that compared positive and negative controls, latanoprost without BAK, latanoprost with BAK, and placebo.Results: A castor oil concentration of 0.15% produced a micelle formulation with a diameter of < 100 nm. This micelle formulation had unique characteristics that were not mimicked when either the surfactant or the oil was changed. The physicochemical characteristics in multiple batches of the micelle formulation did not vary significantly between batches. Long-term and accelerated stability studies showed latanoprost potency remained constant for 24 months at 25°C/75% relative humidity (RH) and at 40°C/25% RH for 6 months.Conclusion: The micelle formulation technology system is capable of solubilizing latanoprost in an ophthalmic formulation without the need for BAK. The system is stable at room temperature.Keywords: open angle glaucoma, micelle formulation, benzalkonium chloride, latanoprost

An aminoglycoside, tobramycin sulfate (TbS), was complexed with hexadecanoic acid (HdA), resulting in a TbS/HdA complex with a repeat unit of 5.3 nm of a lamellar nanostructure. The nanometer-sized TbS/HdA particles were produced using poloxamer 188 as a dispersing agent. The particles were agglomerate-free with sizes in the range of 90-450 nm. The particle size was controlled by optimizing the homogenization conditions and the concentration of poloxamer-188. The lamellar nanostructure of the TbS/HdA complex was retained in the nanoparticle cores, even after the rigorous homogenization step. These core-shell-type nanoparticles were called lamellosomes because each particle consisted of a TbS/HdA lamellar core surrounded by a crown of hydrophilic poloxamer. The ζ-potentials of nanoparticles were in the range of -20 to -26 mV and did not aggregate even after exposing them up to the concentrations of 0.2 mol  L -1 NaCl. However, the nanoparticles were sensitive to the changes in the pH in terms of their aggregation or disintegration. Thus, the steric effects and ionic charge seem to be responsible for the stabilization of the nanoparticles. The TbS/HdA matrix or HdA lamella could dissolve dexamethasone up to ∼2% (w/w) without causing crystallization. The release of the entrapped drug was significantly retarded. The TbS/HdA lamellosomes could serve as aminoglycoside carriers, which can further load drugs, showing potential as a multidrug cargo., Competing Interests: The authors declare no competing financial interest., (© 2024 The Authors. Published by American Chemical Society.)

The study aims to prepare and characterize a novel paclitaxel (PtX) preconcentrate formulation using polymer and lipid excipients that forms nanodispersion upon dilution. The goal was to understand the mechanism of nanodispersion formation and its properties. The water-insoluble PtX was dissolved in organic solvents containing ethanol, polyethylene glycol (PEG400), povidone (PVP), caprylic acid (CA), and sodium cholesterol sulfate (CS). This formulation was diluted in 5% w/v dextrose medium to form PtX nanodispersion, which was assessed for particle size, stability, in-vitro/in-vivo dissociation and protein binding. Transmission electron microscopy (TEM), Small Angle Neutron Scattering (SANS), and Molecular Dynamics (MD) simulations were used to analyse the structure of the nanoparticles. The formulation was a clear, slightly yellow solution. The PtX nanodispersion displays particle size of ~ 100 nm with a zeta potential of -25, and the pH of 4.0. It displayed nearly spherical coacervate nanoparticles with a sponge-like structure, lacking internal structure order as revealed by TEM and SANS. MD simulations confirmed self-assembly of PtX and excipients forming nanoparticles. In vitro dissociation studies in simulated plasma demonstrated rapid dissociation of nanodispersion, releasing free PtX that immediately binds to plasma proteins. In vivo studies in rabbits corroborated these findings, showing rapid dissolution. The results present a novel formulation design that forms sponge-like coacervate nanoparticle due to complimentary interactions of the excipients that otherwise are unable to self-assemble under similar conditions of dilution. This alternative formulation solves the limitations of currently marketed PtX products and can provide its effective delivery in clinical settings., Competing Interests: Declarations. Conflict of Interest: The authors were employees of Sun Pharma Advanced Research Company who sponsored the project. The authors declare no other known competing interest., (© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.)

Purpose: The purpose of this study was to compare the efficacy, and ocular pharmacokinetics of a new 0.04% w/v bis in die means twice a day (BID) ophthalmic solution and marketed 0.05% w/v quater in die means four times a day (QID) ophthalmic emulsion of difluprednate in New Zealand white (NZW) rabbits. Methods: The preclinical proof of concept was established in paracentesis-induced acute inflammation, endotoxin-induced acute uveitis, and bovine serum albumin-induced chronic uveitis in NZW rabbit animal models. A comparison of clinical score, total cell count, and total protein was performed to determine efficacy. An ocular pharmacokinetic study was conducted to study the influence of the vehicle on the ocular absorption of the drug. Results: In both uveitis models, the new solution formulation and marketed emulsion formulation inhibited total clinical score, total cell count, PGE 2, and total protein significantly more than the placebo and lipopolysaccharide (disease control) groups and were comparable. In an ocular pharmacokinetic study, the C max and AUC 0-t of difluoroprednisolone 17-butyrate in humor were ∼2-fold higher after 14 days' instillation of new solution formulation (0.04% w/v, BID) compared with 14 days' instillation of marketed emulsion (0.05% w/v, QID). Conclusions: The study demonstrated that the efficacy of the solution formulation at a lower dose and reduced dosing regimen were comparable to that of the emulsion formulation. The reduction in strength and regimen may result in improved patient adherence and outcomes.

Purpose: This article aims to describe a preclinical proof of concept for a novel once-a-day (OD) brimonidine ophthalmic nanosuspension. Methods: The preclinical proof of concept was established using New Zealand white rabbits as animal models. Dose-finding, multiple-dose efficacy, ocular pharmacokinetic, and hemodynamic studies were performed in normotensive rabbits. Steroid-induced ocular hypertension model in rabbits was used to study efficacy in glaucomatous pathophysiology. The test (0.35% OD suspension) and reference (0.15% three times a day [TID] solution) were compared. Results: The intraocular pressure (IOP) reduction was sustained for 0.35% and 0.5% strengths but not for other lower strengths tested or reference strengths. A 0.35% OD suspension reduced IOP >2 mmHg after 24 h of dosing, which was not seen with the reference. After multiple dosing, 0.35% OD suspension reduced IOP by 4-6 mmHg after 24 h, which was comparable to the 0.15% TID reference solution. An ocular pharmacokinetic study showed that the brimonidine was rapidly absorbed and distributed throughout the eye after topical administration. Concentration was higher in tissues with high α 2 receptors, such as cornea-conjunctiva, iris/ciliary body, and choroid/retina. The steady-state concentrations in these organs were also significant after 24 h of the last dose. There was an indication of increased plasma levels, so a hemodynamic study was performed to assess any adverse effects. All hemodynamic parameters were normal and no new unusual safety findings were observed. Conclusions: The study demonstrated that the novel brimonidine 0.35% ophthalmic nanosuspension is both safe and effective when administered OD and is comparable to the marketed reference formulation administered TID.

Purpose : Many intraocular pressure (IOP)-lowering medications contain benzalkonium chloride (BAK), a preservative associated with unfavorable outcomes.A formulation of latanoprost 0.005% ophthalmic without BAK is approved by the FDA and indicated for reduction of IOP in patients with open-angle glaucoma or ocular hypertension. We present two preclinical studies of latanoprost 0.005% BAK-free vs latanoprost with BAK; one examining plasma and ocular tissue pharmacokinetics (PK) in New Zealand white rabbits, and one comparing in vivo IOP-lowering efficacy in healthy beagles. Methods : In the PK study, one drop of treatment (latanoprost BAK-free or latanoprost with BAK) was instilled into both eyes of rabbits in each treatment group (n = 18). At 0.25, 0.5, 1, 4, 6, and 24 hours postdose, three rabbits per study group underwent terminal blood and tissue collection.In the IOP study, in the first dosing period, both eyes of each beagle received either 1 drop latanoprost BAK-free or latanoprost with BAK, once daily for 10 days. After a 10-day washout period, a second 10-day dosing period was conducted and latanoprost BAK-free or latanoprost with BAK were dosed in the opposite eyes, respectively. IOP measurements were taken at 1, 6, and 12 hours postdose. Results : The maximum plasma concentration for latanoprost BAK-free and latanoprost with BAK occurred 0.25 hours after administration (174.1 vs 217.2 pg/mL, respectively). Area under the concentration time curve from zero to infinity was highest in aqueous humor for latanoprost BAK-free and latanoprost with BAK (133.1 vs 119.6 hr·ng/mL, respectively) and was not estimable in vitreous humor. In beagles, once-daily administration of latanoprost BAK-free or latanoprost with BAK led to a significant reduction in IOP vs baseline ( P < .001); there was no difference between groups ( P > .05). Conclusions : Latanoprost BAK-free showed comparable activity in reducing IOP, and comparable plasma and ocular PK parameters to latanoprost with BAK.

Despite poor bioavailability of the drug and in vivo stability, curcumin has been reported for many pharmacological activities. Considering the potential of dendrimers as a drug delivery system, current research work is focused on the formulation and characterization of G4 PAMAM dendrimer-Palmitic acid core-shell nanoparticle-containing curcumin as antistress therapeutics to maximize the bioavailability of curcumin. Various formulations were prepared using different concentrations of palmitic acid and an optimized ratio of dendrimer and curcumin. All formulations were investigated for evaluation of physicochemical parameters, encapsulation efficiency, and in vitro release. Particle size, PDI, zeta-potential, and encapsulation efficiency of final formulation was found to be 257.9 ± 0.365 nm, 0.10 ± 0.004, 3.59 ± 0.167 mV, and 80.87%, respectively. In vitro release studies have shown that 53.62 ± 2.431% of the drug was released after 24 h. In vivo studies pharmacokinetic parameters, drug distribution, pharmacological, and toxicological were also estimated using swiss albino mice. The findings have shown the selected formulation is better than plain curcumin formulation.

The partial phase behavior, rheological, and drug release characteristics of an organogel (OG) composed of water, isooctane and sorbitan esters, sorbitan monopalmitate (Span-40) and poly(oxyethylene)sorbitan monostearate (Polysorbate-60) were studied. Phase diagrams showed decreasing areas of optically isotropic organogel region depending on the surfactant ratio, Kw and drug incorporation. The nonbirefringent, clear isotropic solution suggested the reverse micellar/microemulsion nature of the organogel without any molecular ordering. The increase in drug concentration in OGs leads to increase in the viscosity and sol-gel transition temperature (Tg). Fractal dimension (df) values calculated for different compositions suggested that the density of the tubular network increases with increasing drug concentration in OGs. The release rate of the drug from OGs was found to be non-Fickian through the dialysis membrane. The permeation rate of sumatriptan from pig skin was 0.231 mg/h/cm2 (781.9 nmol/h/cm2). The study indicates potential of OG as a reservoir system for transdermal drug delivery.

The layer-by-layer (LbL) adsorption of anionic polyelectrolytes (PE) and tobramycin sulfate (TbS) multilayers on zinc oxide core particles followed by the controlled core-removal process leads to the formation of ultrathin capsules, which gradually convert to biaqueous vesicles and emulsionlike systems depending on the hydrophilicity/hydrophobicity of the PE backbone, PE/TbS ratio, and Zn2+ concentration. The unique characteristics of the PE/TbS multilayer capsules result because of the formation of PE/TbS/H2O biphasic liquid systems unlike the other LbL capsular systems that form stiff PE coacervates when mixed together in water. This paper investigates the PE/TbS ultrathin capsule to biaqueous vesicle transition and its physicochemical properties.

Ultrathin microcapsules comprised of anionic polyelectrolytes (PE) and a polycationic aminoglycoside (AmG) antibiotic drug were prepared by depositing PE/AmG multilayers on zinc oxide (ZnO) colloid particles using the layer-by-layer self-assembly technique and subsequently dissolving the ZnO templated cores. The polyelectrolytes, dextran sulfate sodium (DxS) and poly(styrenesulfonate) (PSS), were selected owing to their different backbone structure. An aminoglycoside, tobramycin sulfate (TbS), was used for studying DxS/TbS or PSS/TbS multilayer films. The multilayer growth on ZnO cores was characterized by alternating zeta potential values that were different for the DxS/TbS and PSS/TbS multilayers due to the PE chemistry and its interaction with Zn(2+) ions. Transmission and scanning electron microscopy provide evidence of PE/TbS multilayer coating on ZnO core particles. The slow acid-decomposition of the ZnO cores using weak organic acids and the presence of sufficient quantity of Zn(2+) in the dispersion were required to produce antibiotic multilayer capsules. There was no difference in the morphological characteristics of the two types of capsules; although, the yield for [PSS/TbS](5) capsules was significantly higher than for [DxS/TbS](5) capsules which was related to the physicochemical properties of DxS/TbS/Zn(2+) and PSS/TbS/Zn(2+) complexes forming the capsule wall. The TbS quantity in the multilayer films was determined using a quartz crystal microbalance and high performance liquid chromatography techniques which showed less TbS loading in both, capsules and multilayers on planar gold substrate, than the theoretical DxS:TbS or PSS:TbS stoichiometric ratio. The decomposition of the [PE/TbS](6) multilayers was fastest in physiological buffer followed by mannitol and water. The decomposition rate of the [PSS/TbS](6) multilayers was slower than [DxS/TbS](6) monolayers. The incomplete decomposition of DxS/TbS under saline conditions suggests the major role of hydrogen bonding for stability of DxS/TbS multilayers. A combination of hydrogen bonding and hydrophobic interaction between phenyl rings in PSS was responsible for PSS/TbS multilayer stability. In vivo studies in rabbits highlight the safety and sustained drug delivery potential of the PE/AmG microcapsules. The antibiotic walled ultrathin capsules presented here are suitable for sustained ophthalmic antibiotic delivery.

This work includes investigation on solubility enhancement of indomethacin (IND) in the presence of poly(amidoamine) (PAMAM) dendrimers and passive targeting of the PAMAM/IND complex so formed to the inflamed regions in an animal model. The complex formation was confirmed by infrared and (1)H nuclear magnetic resonance spectroscopy methods. Solubility of IND in aqueous G4-PAMAM followed Higuchi's A(N) curve depending on pH of the solubilizing medium. The solubility was decreased upon addition of dendrimer to the IND saturated solution at various pH, indicating aggregation behavior of the PAMAM/IND complex and conforming to the Higuchi's A(N) solubility profile. The in vitro release of IND from the PAMAM/IND complex through a cellophane membrane, from a Franz diffusion cell, showed 79 +/- 3.2% drug release in 24 h. The drug release was further retarded in the presence of human serum albumin (HSA) suggesting the significance of complex HSA binding in altering in vivo behavior of the complex. Intravenous administration of the PAMAM/IND complex formulation in rats showed a two-compartment pharmacokinetic profile. Enhanced effective IND concentrations in the inflamed regions were obtained for the prolonged time period with the PAMAM/IND complex compared to the free drug in arthritic rats indicating preferred accumulation of IND to the inflamed region. The targeting efficiency of PAMAM/IND complex was 2.29 times higher compared to free drug. In contrast to the previous investigations, two interesting findings reported here are: (a) solubility behavior of IND in G4-PAMAM dendrimer deviates from linearity with increasing concentrations of dendrimer at acidic to neutral pH values and (b) inspite of lymphatic drainage, retention of PAMAM/IND complexes occurs at the inflammatory site.

Hollow microcapsules comprised of poly(styrenesulfonate) (PSS) and a fourth generation poly(amidoamine) dendrimer (4G PAMAM) were prepared by depositing PSS/4G PAMAM multilayers on melamine formaldehyde (MF) colloid particles by the layer-by-layer self-assembly technique and subsequently dissolving the templated cores. The PSS/4G PAMAM layers were unstable toward the core removal procedure (pH approximately 1), resulting in a low yield of intact hollow capsules (<10% for 3.5 microm diameter MF templates). Stretching of the multilayer film due to core swelling during MF core dissolution leads to partial or complete destruction of capsules, giving discrete PSS-4G PAMAM complexes. Yields were increased by increasing inter- and intramolecular attractive forces between the PSS chains in the capsules through electrostatic, hydrophobic, and a combination of these interactions. The yields, however, were practically unaffected by enhancing such effects between dendrimer molecules. Transmission electron microscopy and scanning force microscopy measurements show no deformation for 3.5 microm capsules stabilized through the various interactions stated above. Further, capsules were filled with low molecular weight dextran sulfate and subsequently loaded with a model, therapeutically active molecule, doxorubicin hydrochloride (DOX). Release of DOX from the capsules was also studied to highlight the drug delivery potential of the dendrimer-based microcapsules.

Spherical hydroxyapatite cores were prepared by using carboxylic acid terminated half-generation poly(amidoamine) (PAMAM) dendrimer as templates or crystal modifiers. The hydroxyapatite cores were characterized by infrared spectroscopy (IR), X-ray diffraction (XRD) and transmission electron microscopy (TEM). The spherical core formation depended on phosphate saturation, pH of the simulated body fluid (SBF) and rate of crystal growth. Hydroxyapatite so formed was amorphous and a mixture of various calcium phosphates. Ca/P ratio determination which showed phosphate rich apatite formation. Hydroxyapatite ores were coated with a sugar layer followed by hemoglobin to obtain aquasomes. Aquasomes were characterized for size, hemoglobin loading, oxygen-binding characteristics and storage stability. The nanometric sized aquasome formulation could load approximately 13.7 mg hemoglobin per g of core and retained oxygen-affinity and cooperativity and stability for at least 30 days. Formulation efficacy was tested in albino rats and indicated its potential utility as blood-substitute.

Polyamidoamine (PAMAM) dendrimers were prepared by linking methyl methacrylate and ethylenediamine successively on an amine core. Surface modification of PAMAM dendrimer was done by fatty acid grafting converting them to a unimolecular micellar system (Dendrimer grafts). IR, 1H NMR, 13C NMR studies confirmed the structure. The drug 5-fluorouracil (5-FU) was entrapped in dendrimer grafts. The effects of various solvents (ethanol, dichloromethane, tetrahydrofuran), pH and ionic strength on solubilization of 5-FU were determined. Phospholipid was further coated on the dendrimer grafts. The product was lyophilized and obtained as yellowish-white powder. Average particle size was ca. 375 nm as determined by Malvern's Mastersizer 4. Drug loading was ca. 53% by weight. Stability studies were conducted for 1 month at room temperature and 40 degrees C, where the systems were relatively stable. Release rate was sustained across cellulose tubing in PBS. In vivo studies were performed in albino rats and pharmacokinetic parameters and bioavailability were determined from the plasma profile of 5-FU. The phospholipid coated dendrimer graft formulation was found to be more effective orally than free drug. The lymphatic uptake was also increased indicating absorption of the developed formulation through the lymphatic route.

An active encapsulation method to obtain high entrapment in liposomes is described. The method harnesses the ability of dendrimer to interact with oppositely charged phospholipid and solubilize acidic drugs in their interior. The high drug entrapment in liposomes is due to the enhanced entrapment of dendrimer, which creates sink in the liposomal aqueous compartment where the methotrexate (MTX) molecules are fluxed in. The encapsulation increases with dendrimer generation. The release of bioactive was also decreased by this method. The method may be useful to entrap drugs with relatively high therapeutic dose.

Low entrapment of drugs into liposomes is a serious challenge in their commercial application. 6-Mercaptopurine (6-MP), an antineoplastic agent, is such a drug with low entrapment efficiency (EE). We devised their lipophilic derivatization as a means of enhancing EE by covalently coupling 6-MP with glyceryl monostearate (GMS) via a succinic anhydride spacer. This prodrug had an improved partition coefficient value of 25.16 compared to 1.22 for free drug, confirming higher lipophilicity. A hydrolysis rate study of prodrug indicated 2.90%, 12.5%, 24.1%, and 25.1% hydrolysis in phosphate buffered saline (PBS) (pH 7.4) and 10%, 20%, and 30% serum, respectively. Liposomes of phosphatidylcholine (PC)/sphingomyelin, cholesterol, and dicetyl phosphate bearing drug or prodrug were prepared by shaking by hand and sonication methods. The EE was found to increase from 1.92% for free drug to 91.8% for drug-conjugate. An in vitro cell line toxicity study on L1210 leukemia cells showed improved performance of liposome-encapsulated drug-conjugate compared to free drug. The plasma drug level profile following administration of free drug and the liposomal formulation containing prodrug (HE liposome) manifested a higher sustained level of the latter, which was further improved in case of sphingomyelin-containing liposomes (STHE liposome). The pharmacokinetic parameters revealed an increase in half-life, from 61 min to 120 min for the HE liposomes and 296 min for the STHE liposomes. Therefore, increased entrapment was made possible through lipophilic derivatization, and it was subsequently tested in vivo.

Fine-multiple (water-in-oil-in-water) emulsions were prepared by two-step emulsification using sonication. They were coated with concanavalin-A (Con-A) by three methods. The one involving covalent coupling of Con-A to the multiple emulsion incorporated anchor was better compared with lipid derivatized Con-A anchoring or the glutaraldehyde-based cross-linking method, as shown by the faster rate of dextran-induced aggregation. The selected multiple emulsions were characterized by physical properties such as droplet size, encapsulation efficiency, and zeta potential. Stability parameters such as droplet size, creaming, leakage, and aggregation as a function of relative turbidity were monitored over a 1-month period, which revealed good stability of the formulations. The release profile of 6-mercaptopurine followed zero-order kinetics. Pharmacokinetic studies showed an increase in half-life and bioavailability from multiple emulsion formulations administered intravenously. There was prolonged retention of drug in various tissues of rats when treated with Con-A-coated multiple emulsion as compared with uncoated one. Our study demonstrates the suitability of fine-multiple emulsion for intravenous administration and the potential for prolonged retention of drugs and targeting in biological systems.

Long-circulating lipospheres containing 6-mercaptopurine (6-MP) were prepared by solidification of warm microemulsion at low temperature. Palmitoyl PEG was incorporated in the system to confer stealth-type nature. The size of lipospheres was in the range of 60-70 nm and was inversely proportional to sonication time. The size range was attained after 8 h. of sonication. The entrapped 6-MP contained 0.12 mmol/mole of lipid. The coating efficiency of 63-71% was attained. The zeta potential substantially decreased after PEG coating, however, the lipospheres were stable due to steric repulsion and exhibited no aggregation. The release of 6-MP was found to be 18-25% of administered dose in 24 h. and followed a mixed profile for stealth lipospheres. The percent dose remaining in plasma was found to be high even after 24 h as compared to control, indicating an increase in circulation time of lipospheres. Tissue accumulation of drug correlated with the pharmacokinetic behavior of lipospheres. The system seems to be an ideal carrier for anticancer drug delivery.

A stable multiple emulsion containing rifampicin in the internal aqueous phase was prepared by the incorporation of additives in both aqueous and oily phases. The formulation and process variables were optimized for primary and secondary emulsification. Drug release studies were performed on selected multiple emulsions to observe the effect of dilution. The release data were fitted to the Higuchi equation for slab and spherical geometry and effective diffusion coefficients were calculated. Stability studies for three months revealed good stability of the multiple emulsions with respect to creaming, phase separation, viscosity change, drug leakage, change in droplet size upon storage and exposure to osmotic and shear stress. The in vivo studies performed with stable multiple emulsions administered orally in human volunteers showed prolonged plasma drug levels. The multiple emulsions were found suitable for an improved tuberculosis therapy.

The present investigation reports a new family of lipid nanoparticles biomimetic of lipoproteins, lipoprotein-mimicking biovectorized systems (LMBVs), for the delivery of methotrexate. LMBVs were prepared by microemulsion congealing technique, and the composition and process were optimized. The palmitoylpolyethylene glycol 4000 (p-PEG 4000) was anchored on LMBVs as apoprotein analogue. Various formulations were prepared and characterized for size and polydispersity, zeta potential, drug entrapment efficiency, anchoring efficiency, release kinetics, pharmacokinetics and tissue distribution. The size was 70-76 nm and the polydispersity was 0.09-0.18. The zeta potential was -63.2 which was reduced to -19.3 after p-PEG 4000 coating. Entrapment efficiency varied from 22.6% to 30.2%. Anchoring efficiency was 74.0 +/- 3.9%. The drug release showed zero-order profile. Their circulation half-life was enhanced and exhibited capability to accumulate in tissues for longer periods. The composition of lipidic part of LMBVs and p-PEG 4000 anchoring impart similarity with natural lipoproteins in terms of in vivo behaviour. This new drug carrier named LMBVs, holds promise for targeting and systemic controlled release, which may prove effective in the treatment of various types of cancer.

An attempt was made to improve the pharmacokinetic behaviour of 5-fluorouracil (5-FU) by incorporating it into lipoprotein imitating synthetic carrier 'supramolecular biovector (SMBV)' which is an important prerequisite for achieving its better therapeutic performance against cancer. The polysaccharide core of SMBVs was prepared by ionotropic gelation technique by cross-linking polyguluronate units in the alginate molecules with calcium ions to form so called 'egg-box structure'. The formulation and process variables were optimized to obtain particles of nanometer size range. Hydrophobization was carried out by fatty-acylation on the surface followed by phospholipid coating. Palmitoyl polyethylene glycol (p-PEG) was anchored to impart stealth behaviour. The scanning electron microscopy showed discrete spheres of average diameter 748 nm. Polydispersity was estimated to be 0.37. Overall zeta potential was -21.3 mV. The drug loading capacity and encapsulation efficiency was found to be 10.0% and 97.9%, respectively. The release from drug solution (AP) followed zero-order kinetics. Higuchi release pattern was obtained for egg-box complex cores (AP1) while first-order pattern was followed for fatty acylated (AP2) and lipid coated cores before (AP3) and after p-PEG anchoring (AP4). The amount of drug liberated in 24 h was in the order AP > AP1 > AP2 > AP4 > AP3. The release pattern obtained was a combined effect of drug diffusion through egg-box matrix as well as partitioning in hydrophobic layer and p-PEG layer around the SMBV. The stability study showed negligible leakage and no appreciable change in particle size upon storage at different temperatures which is an indication of good stability of SMBV formulation. The plasma clearance data revealed increase in circulation half-life of drug and bioavailability. Tissue distribution data obtained was a result of competitive uptake of formulations from tissue macrophages and lymphatics depending upon its surface characteristics and residence period in vascular system. The enhanced delivery of drug to lymphatics and improvement in its half-life render SMBVs useful for control of metastasis and tumour growth.

A proniosome based transdermal drug delivery system of levonorgestrel (LN) was developed and extensively characterized both in vitro and in vivo. The proniosomal structure was liquid crystalline-compact niosomes hybrid which could be converted into niosomes upon hydration. The system was evaluated in vitro for drug loading, rate of hydration (spontaneity), vesicle size, polydispersity, entrapment efficiency and drug diffusion across rat skin. The effect of composition of formulation, amount of drug, type of Spans, alcohols and sonication time on transdermal permeation profile was observed. The stability studies were performed at 4 degrees C and at room temperature. The biological assay for progestational activity included endometrial assay and inhibition with the formation of corpora lutea. The study demonstrated the utility of proniosomal transdermal patch bearing levonorgestrel for effective contraception.

The effects of drug concentration in internal aqueous phase of stabilized w/o/w emulsion and additives in oleaginous phase on release characteristics of isoniazid were investigated. The release was significantly effected by both of the formulation variables. The release was enhanced initially with increasing concentration of drug in internal aqueous phase followed by a steady release at high concentration of isoniazid. The release declined substantially in the presence of aluminum tristearate, cetostearyl alcohol, and cholesterol, and it increased with egg lecithin and oleic acid in oily phase. The bioavailability was increased with a multiple-emulsion formulation.

The influence of pulsed current duty cycle, addition of electrically neutral species and pH on iontophoretic transdermal delivery of an organic ion-pair salbutamol:methyl orange through excised rabbit abdominal skin is described. It was compared with salbutamol sulphate and salbutamol:sulphate ion-pair. It was found that there exists an optimum duty cycle range (1:3-1:4) at which iontophoretic flux of the ion-pair was at a maximum because of partition-electric current synchronization. Addition of mannitol decreases the flux of the ion-pair showing the important role of electroosmosis in ion-pair transport. The extremes of pH decrease the flux rates.

Multiple emulsions with an oily liquid membrane (w/o/w) bearing isoniazid were prepared by an improved 2 x 2 step emulsification technique. Both of the interfaces of the liquid membrane were stabilized by using microcrystalline cellulose (MCC) in external as well as internal aqueous phases. The emulsions were characterized for droplet size, percent formation of multiple emulsion, release rate effect of Tween-80 in external phase, phase volume ratio on release, and stability during aging at various storage conditions. The droplet size was small and yield of multiple emulsion was fairly good. The increasing concentration of MCC in either internal or external phase increased the droplet size. The system holds promise in tuberculosis therapy.

Fine-multiple emulsions bearing 6-mercaptopurine (6-MP) in internal aqueous phase were prepared by two step emulsification using sonication technique. It was coated with Concanavalin-A (Con-A) using carbodiimide method to obtain lectin-functionalized multiple emulsions. The Con-A coated multiple emulsion was characterized for antitumour activity on murine leukemia cell line L-1210 in vitro and compared with uncoated multiple emulsion and free drug. An increased uptake and cytotoxicity were observed for Con-A coated multiple emulsion in vitro. The IC50 was decreased upto 4-fold with Con-A coated emulsion. In vivo antitumour activity was seen by recording survival times of mice injected with L-1210 cells i.v. or i.p. The mean survival time was found to increase upon treatment with Con-A coated multiple emulsion. The tumour cell count in the peritoneal cavity was decreased significantly when animal was treated by i.p. route while there was no significant difference when it was treated by i.v. route. The normal peritoneal cells remained unaltered in number and blood parameters were also restored on treatment to tumour bearing mice. The formulation was found to be effective for the treatment of cancer.

Mesophasic proliposomal system for levonorgestrel was developed and evaluated both in vitro and in vivo. The vesicles were mostly unilamellar, however, few vesicles were multilamellar which budded off spontaneously upon hydration. The release of drug from this system adhered to zero order kinetics. The effect of alcohols and volatile oils on transdermal flux was investigated. The flux was found to be the highest for alcohol, and followed by that for lemon oil. The in vivo studies indicate the requirement for a loading dose, since, a significant lag phase was observed before the therapeutic levels were reached. This system was, however, superior to the PEG-based ointment system which was employed as the control formulation. The results demonstrate the potential of proliposomal system for efficacious transdermal delivery of hydrophobic drugs.

The conventional W/O/W emulsions are readily taken up by the reticuloendothelial system (RES) so that it is necessary to develop either stealth type or tissue specific multiple emulsion for effective targeting. A multiple emulsion system W/O/W containing rifampicin as encapsulant (W/O/W) was prepared. The droplet size was kept small to study targeting independent of passive embolism of larger droplets in the lung capillaries. It was characterised in vitro for drug release through a treated cellophane membrane. A prolonged first order drug release was observed. The W/O/W multiple emulsion system was coated with an o-palmitoyl derivative of mannan (mol.wt. 20,000) to assess its toxicity in vitro and its distribution behaviour in vivo. The multiple emulsion was found to be non toxic at 0.2 ml formulation/10(6) cells level in presence or absence of serum. An intravenous injection of the polysaccharide coated multiple emulsion was given and the tissue distribution of the drug after 1 h and 24 h was investigated. A significant enhancement in lung uptake and a decreased internalisation by spleen was noticed.

Nanopseudolatex was prepared for sustained ophthalmic delivery. It was prepared by a solvent injection method without the use of any stabilizer. The acrylate copolymers Eudragit RLPM and RSPM were used as carrier materials. Their formation was confirmed by electron microscopy. The system was extensively characterized for particle size, viscosity, sedimentation volume, encapsulation efficiency, in vitro release profile and pharmacodynamic properties. The particle size was found to be stirring rate dependent above the injection rate of 1 ml/min. Only at slow stirring rates it was temperature dependent. There was no sedimentation for about 60 d. The viscosity was 23-27 cps which was particle size dependent. The results show an excellent encapsulation efficiency of about 94-98%. Release studies showed slow and consistent drug release from the formulation. However, Eudragit RSPM showed comparatively longer release than Eudragit RLPM nanosuspensions. Using this method we have developed a new formulation of diclofenac diethyl ammonium which showed increased therapeutic efficacy as compared with eye drops.